Nature Communications (Jun 2022)

Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells

  • Eishiro Mizukoshi,
  • Hidetoshi Nakagawa,
  • Toshikatsu Tamai,
  • Masaaki Kitahara,
  • Kazumi Fushimi,
  • Kouki Nio,
  • Takeshi Terashima,
  • Noriho Iida,
  • Kuniaki Arai,
  • Tatsuya Yamashita,
  • Taro Yamashita,
  • Yoshio Sakai,
  • Masao Honda,
  • Shuichi Kaneko

DOI
https://doi.org/10.1038/s41467-022-30861-z
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

The success of peptide vaccine treatment in cancer relies on the build-up of an efficient cytotoxic T cell response against the tumour antigen. Authors show here that tumour-specific memory CD8 T cells are able to persist and possibly even proliferate in the peripheral blood of long-surviving hepatocellular carcinoma patients.